Medtronic
30-Second Executive Brief
Executive Assessment
Medtronic functions as a systemically important institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, with accelerating strategic relevance.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as systemically important institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Systemically Important Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- Very High
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 6
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A diversified global medical device company that delivered its highest annual revenue growth in 10 years in fiscal 2026, with FY26 worldwide revenue of $36.364 billion (up 8.4% as reported, 5.8% organically). Medtronic completed its acquisition of SPR in July 2026, expanding access to minimally invasive, non-opioid chronic and acute pain treatment, raised its quarterly dividend for a 49th consecutive year, and guided to 6.75%-7.25% organic revenue growth for FY27.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Earnings-call mentions
Mentioned by Tempus AI
“Announced study results from the ALERT trial in collaboration with Medtronic showing that Tempus' AI-driven EHR notifications increased life-saving heart valve procedures by 40% for patients with significant disease.”
SEC 8-K exhibit (0001193125-26-206317) · May 5, 2026
Federal contract disclosures
Department of Veterans Affairs — $7,755,749: EXPRESS REPORT OCT & NOV 2025 (FY26)
USAspending.gov · Oct 1, 2025
Department of Veterans Affairs — $4,605,465: EXPRESS REPORT SEPTEMBER 2025
USAspending.gov · Sep 1, 2025
Department of Veterans Affairs — $4,069,120: EXPRESS REPORT DECEMBER 2025
USAspending.gov · Dec 1, 2025
Department of Veterans Affairs — $3,681,157: EXPRESS REPORT JAN 2026
USAspending.gov · Jan 1, 2026
Department of Veterans Affairs — $3,647,812: EXPRESS REPORT FEB 2026
USAspending.gov · Feb 1, 2026
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- PR Newswire — Medtronic reports fourth quarter and full year fiscal 2026 resultscompany
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Medtronic — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Medtronic's FY27 guidance implies management believes the growth reacceleration is durable, not a one-off
33% confidenceMedtronic delivered its highest annual revenue growth in a decade in FY2026 (8.4% as reported) and guided to 6.75%-7.25% organic growth for FY27 -- a guidance range above its FY2026 organic rate of 5.8% -- while also extending its dividend increase streak to 49 consecutive years.
This is InsightNodes' own interpretive read: guiding to organic growth above the prior year's already decade-high rate is a notable statement of confidence for a company of Medtronic's scale and diversification, since large diversified medtech portfolios typically see growth normalize rather than accelerate further after a strong year -- if Medtronic delivers on this FY27 guidance, it would suggest genuine multi-segment momentum (cardiac, diabetes, pain management via SPR) rather than a single product cycle, though the breadth of the portfolio also means several segments would need to execute well simultaneously.
InsightNodes analysis of Medtronic FY2026 results · Aug 14, 2026
Medtronic's Timeline
A sourced, dated history of Medtronic's key moments — founding to present.
Jun 2026 · FY2026 results: highest revenue growth in 10 years
Medtronic reported full fiscal year 2026 worldwide revenue of $36.364 billion, up 8.4% as reported and 5.8% organically, its highest annual revenue growth rate in a decade.
Jul 2026 · Completes SPR acquisition
Medtronic completed its acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain.
How These Connections Evolved
How a relationship changed over time, not just its current state — sourced, dated, and traceable.
Medtronic ↔ Healthcare & Life Sciences
2012–2018 · Pre-portfolio-restructuring sector position
Medtronic's position within the broader healthcare & life sciences sector predates its more recent 2020s portfolio restructuring toward higher-growth diabetes and surgical robotics segments.
Now
Medtronic operates across cardiac, diabetes, neuroscience, and surgical technology segments of the healthcare and life sciences industry.